Cost Effectiveness of Imatinib, Dasatinib, and Nilotinib as First-Line Treatment for Chronic-Phase Chronic Myeloid Leukemia in China - Concepedia

Concepedia

Publication | Closed Access

Cost Effectiveness of Imatinib, Dasatinib, and Nilotinib as First-Line Treatment for Chronic-Phase Chronic Myeloid Leukemia in China

26

Citations

17

References

2017

Year

Na Li, Bin Zheng, Hongfu Cai, Jing Yang, Xiaofeng Luo, Lizhu Weng, Feng-Mei Zhan, Mao-Bai Liu

Clinical Drug Investigation

Hematological MalignancyMedicineHematologyMyeloid NeoplasiaFirst-line TreatmentCost EffectivenessOncologyRadiation OncologyHealth Sciences

References

	Year	Citations

Page 1